KALA BIO, Inc. (NASDAQ:KALA) Short Interest Update

KALA BIO, Inc. (NASDAQ:KALA) was the recipient of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totalling 65,800 shares, a decrease of 77.7% from the June 30th total of 295,200 shares. Approximately 3.0% of the shares of the stock are sold short. Based on an average daily volume of 231,600 shares, the short-interest ratio is presently 0.3 days.

KALA BIO Trading Down 4.6 %

Shares of KALA BIO stock traded down $0.34 during trading on Friday, hitting $6.91. The stock had a trading volume of 32,804 shares, compared to its average volume of 119,553. The company has a quick ratio of 4.22, a current ratio of 4.22 and a debt-to-equity ratio of 4.92. The company has a market capitalization of $19.47 million, a PE ratio of -0.46 and a beta of -2.04. KALA BIO has a 1 year low of $4.21 and a 1 year high of $15.94. The stock has a 50 day simple moving average of $6.53 and a 200 day simple moving average of $7.02.

KALA BIO (NASDAQ:KALA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($4.20) earnings per share for the quarter, missing the consensus estimate of ($2.89) by ($1.31). On average, research analysts expect that KALA BIO will post -14.49 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on KALA. HC Wainwright cut their price objective on KALA BIO from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Friday, May 17th. Oppenheimer reaffirmed an “outperform” rating and set a $15.00 target price on shares of KALA BIO in a report on Monday, April 1st.

Insiders Place Their Bets

In other news, CEO Mark T. Iwicki sold 15,168 shares of KALA BIO stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $4.75, for a total transaction of $72,048.00. Following the transaction, the chief executive officer now directly owns 263,755 shares in the company, valued at approximately $1,252,836.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other KALA BIO news, CEO Mark T. Iwicki sold 15,168 shares of the company’s stock in a transaction dated Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total value of $72,048.00. Following the completion of the sale, the chief executive officer now directly owns 263,755 shares of the company’s stock, valued at approximately $1,252,836.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Mark T. Iwicki sold 7,392 shares of KALA BIO stock in a transaction that occurred on Friday, May 31st. The stock was sold at an average price of $6.09, for a total transaction of $45,017.28. Following the completion of the transaction, the chief executive officer now directly owns 278,923 shares in the company, valued at approximately $1,698,641.07. The disclosure for this sale can be found here. Insiders sold 35,255 shares of company stock worth $182,564 over the last ninety days. Company insiders own 13.40% of the company’s stock.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in KALA BIO stock. Tower Research Capital LLC TRC acquired a new position in shares of KALA BIO, Inc. (NASDAQ:KALA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,357 shares of the company’s stock, valued at approximately $30,000. Tower Research Capital LLC TRC owned 0.16% of KALA BIO at the end of the most recent quarter. 24.61% of the stock is currently owned by institutional investors and hedge funds.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.